135 related articles for article (PubMed ID: 15162995)
41. FDG-PET in staging lung cancer: how does it change the algorithm?
Verhagen AF; Bootsma GP; Tjan-Heijnen VC; van der Wilt GJ; Cox AL; Brouwer MH; Corstens FH; Oyen WJ
Lung Cancer; 2004 May; 44(2):175-81. PubMed ID: 15084382
[TBL] [Abstract][Full Text] [Related]
42. 18F-deoxyglucose uptake in stage I non-small-cell lung cancer: time to move to randomized trials.
De Ruysscher D
J Thorac Oncol; 2014 Jan; 9(1):5-6. PubMed ID: 24346088
[No Abstract] [Full Text] [Related]
43. Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers.
Nakamura H; Hirata T; Kitamura H; Nishikawa J
Ann Thorac Cardiovasc Surg; 2009 Oct; 15(5):304-10. PubMed ID: 19901884
[TBL] [Abstract][Full Text] [Related]
44. Parathyroid adenoma upstaging the lung cancer.
Okuyucu K; Kavakli K; Ozaydın S; Karahatay S; Karatas O; Doğan D
Ann Nucl Med; 2015 May; 29(4):371-4. PubMed ID: 25618011
[TBL] [Abstract][Full Text] [Related]
45. Use of positron emission tomography in initial staging of nonsmall cell lung carcinoma: a regional teaching hospital experience.
Geraldson CT; Stephenson JE; Lagrew JP; Schammel CM; Schammel DP; Greene RA; Bolton WD
Am Surg; 2012 Mar; 78(3):305-8. PubMed ID: 22524768
[TBL] [Abstract][Full Text] [Related]
46. Correlation of Glut-1 glucose transporter expression with.
Higashi K; Ueda Y; Sakurai A; Wang XM; Xu L; Murakami M; Seki H; Oguchi M; Taki S; Nambu Y; Tonami H; Katsuda S; Yamamoto I
Eur J Nucl Med; 2000 Dec; 27(12):1778-85. PubMed ID: 11189940
[TBL] [Abstract][Full Text] [Related]
47. PET in lung cancer staging.
Coleman RE
Q J Nucl Med; 2001 Sep; 45(3):231-4. PubMed ID: 11788815
[TBL] [Abstract][Full Text] [Related]
48. Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers.
Sun JS; Park KJ; Sheen SS; Yoon JK; Yoon SN; Lee KB; Hwang SC
Lung Cancer; 2009 Nov; 66(2):205-10. PubMed ID: 19203812
[TBL] [Abstract][Full Text] [Related]
49. PET/CT findings for bone marrow carcinosis because of lung adenocarcinoma.
Watanabe K; Shinkai M; Nagai K; Yamaguchi N; Ishigatsubo Y; Kaneko T
J Thorac Oncol; 2013 Nov; 8(11):1456-7. PubMed ID: 24128717
[No Abstract] [Full Text] [Related]
50. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study.
Higashi K; Ito K; Hiramatsu Y; Ishikawa T; Sakuma T; Matsunari I; Kuga G; Miura K; Higuchi T; Tonami H; Yamamoto I
J Nucl Med; 2005 Feb; 46(2):267-73. PubMed ID: 15695786
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
[TBL] [Abstract][Full Text] [Related]
52. [Value of 18F-FDG PET in clinical staging of non-small-cell lung cancer].
Liu SW; Yu JM; Xing LG
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):626-9. PubMed ID: 15634527
[TBL] [Abstract][Full Text] [Related]
53. Multiple distant muscular metastases from non-small cell lung carcinoma evidenced by 18F-FDG PET/CT.
Caobelli F; Pizzocaro C; Guerra UP
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):338-9. PubMed ID: 23809515
[No Abstract] [Full Text] [Related]
54. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
[TBL] [Abstract][Full Text] [Related]
55. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index.
Vesselle H; Salskov A; Turcotte E; Wiens L; Schmidt R; Jordan CD; Vallières E; Wood DE
J Thorac Oncol; 2008 Sep; 3(9):971-8. PubMed ID: 18758298
[TBL] [Abstract][Full Text] [Related]
56. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review.
Mac Manus M; Hicks RJ
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1298-306. PubMed ID: 19028270
[No Abstract] [Full Text] [Related]
57. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment.
Mac Manus MP; Hicks RJ; Ball DL; Kalff V; Matthews JP; Salminen E; Khaw P; Wirth A; Rischin D; McKenzie A
Cancer; 2001 Aug; 92(4):886-95. PubMed ID: 11550162
[TBL] [Abstract][Full Text] [Related]
58. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer.
Berlangieri SU; Scott AM; Knight SR; Fitt GJ; Hennessy OF; Tochon-Danguy HJ; Clarke CP; McKay WJ
Eur J Cardiothorac Surg; 1999 Sep; 16 Suppl 1():S25-30. PubMed ID: 10536941
[TBL] [Abstract][Full Text] [Related]
59. Diagnosis of pulmonary adenocarcinoma due to hip bone metastasis.
Puertas García-Sandoval JP; Valcárcel Díaz A; Calatayud Mora JA
Arch Bronconeumol; 2013 Jan; 49(1):37-8. PubMed ID: 22980134
[No Abstract] [Full Text] [Related]
60. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.
Pyka T; Bundschuh RA; Andratschke N; Mayer B; Specht HM; Papp L; Zsótér N; Essler M
Radiat Oncol; 2015 Apr; 10():100. PubMed ID: 25900186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
